Trump Has A Financial Interest In Hydroxychloroquine? Shocking!

Possibly operating under the "don't upset daddy" rule of White House coverage, the New York Times' story yesterday on the rift between Donald "Moron Vector" Trump and his medical advisors over use of the anti- malarial drug hydroxychloroquine in treating coronavirus managed to bury the lede 23 paragraphs deep.  As many have already speculated, there appear to be financial connections between Moron Vector, his donors, and the drug:

Some associates of Mr. Trump’s have financial interests in the issue. Sanofi’s largest shareholders include Fisher Asset Management, the investment company run by Ken Fisher, a major donor to Republicans, including Mr. Trump. A spokesman for Mr. Fisher declined to comment.

Another investor in both Sanofi and Mylan, another pharmaceutical firm, is Invesco, the fund previously run by Wilbur Ross, the commerce secretary. Mr. Ross said in a statement Monday that he “was not aware that Invesco has any investments in companies producing” the drug, “nor do I have any involvement in the decision to explore this as a treatment.”

As of last year, Mr. Trump reported that his three family trusts each had investments in a Dodge & Cox mutual fund, whose largest holding was in Sanofi.

Several generic drugmakers are gearing up to produce hydroxychloroquine pills, including Amneal Pharmaceuticals, whose co-founder Chirag Patel is a member of Trump National Golf Course Bedminster in New Jersey and has golfed with Mr. Trump at least twice since he became president, according to a person who saw them.

There's more at the link about various other charlatans like Rudy Giuliani (but you have to scroll down),

It should surprise absolutely no one with a pulse that our corrupt- to- the- bone narcissist "president" likely has a financial interest in seeing that hydroxychloroquine gains widespread use, though it has yet to be tested as a treatment for coronavirus. 

Meanwhile, has the Times fallen so far that it's willing to bury this information, which otherwise would merit a banner headline and deep- dive investigation?  Maybe the Washington Post should take it from here.